Disruption of a natural process called X-chromosome inactivation (XCI) in immune B-cells — occurring when one X chromosome in females is turned off during development — may directly contribute to the development of systemic lupus erythematosus (SLE), two new studies led by a veterinary professor suggest. According to Montserrat…
News
The Lupus Research Alliance and Genentech have launched a new funding program to support three research projects focused on developing immune-resetting CAR T-cell therapies for lupus. The initiative seeks to deepen the scientific understanding of how these treatments work…
The U.S. Food and Drug Administration (FDA) has approved a self-injected version of Saphnelo (anifrolumab-fnia). Like the original version of Saphnelo, which is given by infusion into the bloodstream every four weeks, the Saphnelo Pen is indicated for use in combination with standard therapy for systemic lupus erythematosus…
This May, organizations will mark Lupus Awareness Month with initiatives and are calling on the lupus community to take action to spread the word. Observed each year, the campaign also includes Lupus Awareness Day on May 10, a key moment to spotlight the challenges faced by people living with…
A combination of two simple lab tests may provide a noninvasive, more reliable way to assess disease activity in systemic lupus erythematosus (SLE) — the most common form of the autoimmune disorder lupus — and detect early kidney involvement, a study suggested. Researchers found that blood levels of galectin-9,…
Biogen is making “strong progress” with enrollment in the AMETHYST study, a Phase 2/3 clinical trial testing the company’s experimental therapy litifilimab (BIIB059) in people with cutaneous lupus erythematosus (CLE). That’s according to Diana Gallagher, MD, Biogen’s…
An under-the-skin, self-administered version of Saphnelo (anifrolumab-fnia) could soon allow people with systemic lupus erythematosus (SLE) to manage their condition at home with the same effectiveness as clinical infusions. According to AstraZeneca, the new subcutaneous formulation provides efficacy comparable to the approved intravenous formulation while significantly reducing the…
A Phase 2 clinical trial testing Galápagos‘ experimental oral therapy GLPG3667 in people with systemic lupus erythematosus (SLE) has failed to meet its main goal, although some promising trends were observed in secondary measures, Galápagos announced. The Phase 2 trial, dubbed GALACELA (NCT05856448), tested two doses of GLPG3667…
Treatment with Benlysta (belimumab) can help people with lupus avoid disease flares and reduce their need for glucocorticoids, according to new analyses of clinical trial data announced by the therapy’s maker, GSK. Roger Abramino Levy, MD, PhD, senior global medical director for rheumatology at GSK, noted that…
The U.S. Food and Drug Administration (FDA) has approved Gazyva (obinutuzumab) as an add-on treatment for adults with lupus nephritis, a form of lupus marked by kidney damage. “The approval of Gazyva by the FDA marks an important step towards a potential new standard of care for…
Recent Posts
- Recognizing patterns is one of my greatest weapons against lupus flares
- Flaws on the X chromosome may directly trigger lupus in women
- Kennedy Ryan novel ‘Reel’ offers real representation of lupus
- Choosing to show up for yourself is a vital part of healing
- Lupus Research Alliance, Genentech fund immune-resetting studies